Jubilant Ingrevia delivered impressive financial performance in the June 2026 quarter, with consolidated net profit rising 41% to ₹106 crore compared to ₹75 crore in the corresponding quarter of the previous year. However, analyst recommendations remain divided following the strong earnings announcement. While Anand Rathi maintains a BUY rating with a revised target price of ₹980/share, Prabhudas Lilladher has issued a HOLD rating with a target price of ₹711, citing valuation concerns at current levels. The company also announced that its Nomination, Remuneration & Compensation Committee approved the grant of 42,298 stock options under the Jubilant Ingrevia Employees Stock Option Scheme 2021, comprising 34,808 Restricted Stock Units (RSUs) and 7,490 Performance Linked Stock Units (PSUs) with an exercise price of Re. 1 per share.
The company's consolidated revenue of ₹1,300.3 crore in Q1FY27 was broadly in line with estimates, as reported by Prabhudas Lilladher's research report dated July 24, 2026. The Chemical Intermediates segment registered strong growth of 38% YoY and 21% QoQ, driven by higher cost pass-through and improved Acetic Anhydride volumes during the quarter. The Nutrition & Health Solutions segment reported growth of 36% YoY and 6% QoQ, supported by higher volumes in Human Nutrition and Niacinamide, along with improved pricing across the Animal Nutrition portfolio. The Specialty Chemicals segment grew 11% YoY and 3% QoQ, aided by commencement of contribution from the USD300mn agrochemical CDMO contract and volume growth across the Fine Chemicals portfolio. In comparison, these business segments had reported topline of ₹xx crore, ₹xx crore, and ₹xx crore respectively in the previous year.
Jubilant Ingrevia reported ~₹2bn EBITDA (up 40% y/y and 22% q/q) in Q1FY27, ahead of estimates, driven by strong pricing growth across Nutrition and Health Solutions (NHS) and Chemical Intermediates (CI), according to Anand Rathi's research report dated July 24, 2026. The company's EBITDA margin rose 162bps y/y and 152bps q/q to 15.3%, aided by CI margin improvement of 641bps y/y and 579bps q/q. EBITDA increased 40% to ₹199.1 crore from ₹142.2 crore a year earlier, while EBITDA margin expanded to 15.3% from 13.7% in the corresponding quarter last year. This improvement in operating margins reflects better cost management and operational efficiency during the quarter.
Earnings Before Interest and Tax (EBIT) for the Speciality Chemicals segment stood at ₹109 crore, followed by Chemical Intermediates at ₹44 crore and Nutrition & Health Solutions at ₹28 crore, according to CNBC TV18. The Chemical Intermediates segment's strong performance was driven by higher cost pass-through and improved Acetic Anhydride volumes, while the Nutrition & Health Solutions segment benefited from higher volumes in Human Nutrition and Niacinamide. However, Prabhudas Lilladher notes that Pyridine and Picoline prices remained under pressure due to continued competitive intensity from Chinese suppliers, which could adversely impact segment margins. The company's EBITDA performance was driven by strong pricing growth across Nutrition and Health Solutions (NHS) and Chemical Intermediates (CI), volume levers in Specialty Chemicals via Agro CDMO contract and faster ramp-up of Human grade B3/premixes in NHS portfolio.
The management maintained FY27 EBITDA guidance at ₹7.5-8bn, with growth drivers including higher Agro CDMO dispatches in Q2 vs. Q1, Fine Chemicals scale-up with personal care molecules, and Human grade B3 ramp to ~70% sooner-than-expected, according to Anand Rathi's report. Prabhudas Lilladher maintains its HOLD rating, noting that at the current market price, the stock trades at 28x FY28E EPS. Based on their SoTP valuation, they derive a target price of ₹711, implying 27x FY28E P/E. The brokerage highlighted that while the recent increase in acetic acid prices is expected to provide a near-term tailwind for the Chemical Intermediates business, any reversal in prices could adversely impact segment margins. Additionally, visibility on incremental order inflows under the agrochemical CDMO contract remains limited at present, which could impact future growth prospects.
